Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, Praveen Aanur et al.|The Lancet|2024Cited by 729
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Chan Gao et al.|Unknown|2023Cited by 0
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Chan Gao et al.|Unknown|2023Cited by 0
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Megan Raymond et al.|Unknown|2023Cited by 0
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid TumorsRui Wang, Michael Quigley, Chan Gao et al.|Unknown|2023Cited by 0